Loading
Life sciences · Journal article
Current Oncology · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy. Methods: We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI-based therapy between 2019 and 2024. Patients were classified according to ABO blood group, and overall survival (OS), progression-free survival (PFS), and treatment response were evaluated. Results: Patients with blood group O had significantly longer OS (18.6 vs. 11.0 months; p < 0.001) and PFS (9.4 vs. 4.2 months; p = 0.001) than patients with non-O blood groups. In multivariable analyses, blood group O remained independently associated with improved OS and PFS. Conclusions: Blood group O may represent a simple and readily available host-related prognostic marker in patients with advanced NSCLC receiving ICI-based therapy. Prospective multicenter studies are required to validate these findings.